DrugPatentWatch Database Preview

Biogen Idec Inc Company Profile

« Back to Dashboard

What is the competitive landscape for BIOGEN IDEC INC, and when can generic versions of BIOGEN IDEC INC drugs launch?

BIOGEN IDEC INC has one approved drug.

There are seven US patents protecting BIOGEN IDEC INC drugs.

There are sixty-three patent family members on BIOGEN IDEC INC drugs in thirty-three countries and twenty supplementary protection certificates in ten countries.

Summary for Biogen Idec Inc

International Patents:	63
US Patents:	7
Tradenames:	1
Ingredients:	1
NDAs:	1
Drug Master File Entries:	4
Patent Litigation for Biogen Idec Inc:	See patent lawsuits for Biogen Idec Inc

Drugs and US Patents for Biogen Idec Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013		RX	Yes	Yes	8,524,773
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013		RX	Yes	No	6,509,376		Y
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013		RX	Yes	No	8,524,773
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013		RX	Yes	No	7,803,840
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013		RX	Yes	Yes	8,399,514

Expired US Patents for Biogen Idec Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	8,524,773
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	8,524,773
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	8,759,393
Biogen Idec Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	8,759,393

Paragraph IV (Patent) Challenges for BIOGEN IDEC INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-releaseCapsules	120 mg and 240 mg		2017-03-27

Non-Orange Book US Patents for Biogen Idec Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,612,110	Utilization of dialkylfumarates
7,915,310	Utilization of dialkylfumarates

International Patents for Biogen Idec Inc Drugs

Country	Document Number	Estimated Expiration
European Patent Office	2680010
China	1182844
European Patent Office	1131065
Spain	2424022
Slovenia	2137537

Supplementary Protection Certificates for Biogen Idec Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014024	Lithuania		PRODUCT NAME: DIMETHYLIS FUMARAS; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2014000069	Germany		PRODUCT NAME: DIMETHYLFUMARAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
488	Luxembourg		PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140130
8	Finland
C/GB03/005	United Kingdom		PRODUCT NAME: D-MEDETOMIDINE (4-((1S)-1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE) AND ITS NON-TOXIC PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE HYDROCHLORIDE; REGISTERED: UK EU/2/02/033/001 20020830

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Biogen Idec
• Biogen Idec Inc
• Bioglan